Clinical Trial Update: A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders [Phase 3]

View source ↗

Summary

Phase III study of RC18 for neuromyelitis optica spectrum disorders has been terminated; no results are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyers Optica Spectrum Disorder

Drugs mentioned

• RC18 (RC18)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Neuromyelitis Optica Spectrum Disorders | Phase 3 | Status: TERMINATED